U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C76H52O46.C9H13NO2
Molecular Weight 1868.4035
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENYLEPHRINE TANNATE

SMILES

CNC[C@H](O)C1=CC(O)=CC=C1.OC2=CC(=CC(O)=C2O)C(=O)OC3=CC(=CC(O)=C3O)C(=O)OC[C@H]4O[C@@H](OC(=O)C5=CC(O)=C(O)C(OC(=O)C6=CC(O)=C(O)C(O)=C6)=C5)[C@H](OC(=O)C7=CC(O)=C(O)C(OC(=O)C8=CC(O)=C(O)C(O)=C8)=C7)[C@@H](OC(=O)C9=CC(O)=C(O)C(OC(=O)C%10=CC(O)=C(O)C(O)=C%10)=C9)[C@@H]4OC(=O)C%11=CC(O)=C(O)C(OC(=O)C%12=CC(O)=C(O)C(O)=C%12)=C%11

InChI

InChIKey=HXLHQWSMCJUVMM-RVLWPPNGSA-N
InChI=1S/C76H52O46.C9H13NO2/c77-32-1-22(2-33(78)53(32)92)67(103)113-47-16-27(11-42(87)58(47)97)66(102)112-21-52-63(119-72(108)28-12-43(88)59(98)48(17-28)114-68(104)23-3-34(79)54(93)35(80)4-23)64(120-73(109)29-13-44(89)60(99)49(18-29)115-69(105)24-5-36(81)55(94)37(82)6-24)65(121-74(110)30-14-45(90)61(100)50(19-30)116-70(106)25-7-38(83)56(95)39(84)8-25)76(118-52)122-75(111)31-15-46(91)62(101)51(20-31)117-71(107)26-9-40(85)57(96)41(86)10-26;1-10-6-9(12)7-3-2-4-8(11)5-7/h1-20,52,63-65,76-101H,21H2;2-5,9-12H,6H2,1H3/t52-,63-,64+,65-,76+;9-/m10/s1

HIDE SMILES / InChI

Molecular Formula C76H52O46
Molecular Weight 1701.1985
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C9H13NO2
Molecular Weight 167.205
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf and https://www.drugs.com/pro/phenylephrine-and-chlorpheniramine-tablets.html

Phenylephrine is a powerful vasoconstrictor. It is used as a nasal decongestant and cardiotonic agent. Phenylephrine is a postsynaptic α1-receptor agonist with little effect on β-receptors of the heart. Parenteral administration of phenylephrine causes a rise in systolic and diastolic pressures, a slight decrease in cardiac output, and a considerable increase in peripheral resistance; most vascular beds are constricted, and renal, splanchnic, cutaneous, and limb blood flows are reduced while coronary blood flow is increased. Phenelephrine also causes pulmonary vessel constriction and subsequent increase in pulmonary arterial pressure. Vasoconstriction in the mucosa of the respiratory tract leads to decreased edema and increased drainage of sinus cavities. In general, α1-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α1-receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/11. Three α1-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: α1A (chromosome 8), α1B (chromosome 5), and α1D (chromosome 20). Phenylephrine appears to act similarly on all three receptor subtypes. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of the α1-receptor activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction. Phenylephrine produces its local and systemic actions by acting on α1-adrenergic receptors peripheral vascular smooth muscle. Stimulation of the α1-adrenergic receptors results in contraction arteriolar smooth muscle in the periphery. Phenylephrine decreases nasal congestion by acting on α1-adrenergic receptors in the arterioles of the nasal mucosa to produce constriction; this leads to decreased edema and increased drainage of the sinus cavities. Phenylephrine is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.

CNS Activity

Curator's Comment: Phenylephrine does not cross the blood–brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
55.0 nM [EC50]
5.9 nM [EC50]
154.88 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VAZCULEP

Approved Use

VAZCULEP (phenylephrine hydrochloride) is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Launch Date

1953
Diagnostic
Phenylephrine Hydrochloride Ophthalmic Solution

Approved Use

Indicated to dilate the pupil

Launch Date

1938
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2959 pg/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4492 pg/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1354 pg/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2346 pg × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3900 pg × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
955.8 pg × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.93 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.64 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.89 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Age Group: 34 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Ischemic colitis...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (acute)
Sources:
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Disc. AE: Chest pain, Jaw pain...
Other AEs: Nervous system disorders, Headache...
AEs leading to
discontinuation/dose reduction:
Chest pain (1 patient)
Jaw pain (1 patient)
Other AEs:
Nervous system disorders (3.6%)
Headache (2.7%)
Gastrointestinal disorders (8%)
Dry mouth (2.7%)
Nausea (3.6%)
Sources:
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Other AEs: Eye pain, Blurred vision...
Other AEs:
Eye pain
Blurred vision
Photophobia
Allergic conjunctivitis
Sources:
250 ug single, intravenous
Recommended
Dose: 250 ug
Route: intravenous
Route: single
Dose: 250 ug
Sources:
unhealthy, adult
AEs

AEs

AESignificanceDosePopulation
Ischemic colitis acute
Disc. AE
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Age Group: 34 years
Sex: M
Population Size: 1
Sources:
Chest pain 1 patient
Disc. AE
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Jaw pain 1 patient
Disc. AE
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Dry mouth 2.7%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Headache 2.7%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Nausea 3.6%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Nervous system disorders 3.6%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Gastrointestinal disorders 8%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Allergic conjunctivitis
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Blurred vision
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Eye pain
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Photophobia
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Effect of alterations of arterial blood pressure and heart rate on segmental dyskinesis during acute myocardial ischemia and following coronary reperfusion.
1975 Jan
Renal injury and salt-sensitive hypertension after exposure to catecholamines.
1999 Jul
Epidural phenylephrine attenuates hypotension induced by alkalinized lidocaine epidural anesthesia.
1999 Jun
Troglitazone inhibits alpha1-adrenoceptor-induced DNA synthesis in vascular smooth muscle cells.
1999 Jun 11
Investigation of the effects of some alkaloidal alpha1-adrenoceptor antagonists on human hyperplastic prostate.
1999 Jun 25
[An unusual episode of angina].
1999 Mar
The use of oral vasopressors in the management of autonomic dysfunction and orthostatic hypotension.
1999 May
Characterization of human recombinant alpha(2A)-adrenoceptors expressed in Chinese hamster lung cells using intracellular Ca(2+) changes: evidence for cross-talk between recombinant alpha(2A)- and native alpha(1)-adrenoceptors.
2000 Apr
Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases.
2000 Apr 11
Alpha(1) adrenergic agonist induction of p21(waf1/cip1) mRNA stability in transfected HepG2 cells correlates with the increased binding of an AU-rich element binding factor.
2000 Apr 21
Purinergic and adrenergic agonists synergize in stimulating vasopressin and oxytocin release.
2000 Dec 1
The influence of indomethacin on the acth secretion induced by central stimulation of adrenergic receptors.
2000 Jun
Role for early growth response-1 protein in alpha(1)-adrenergic stimulation of fibroblast growth factor-2 promoter activity in cardiac myocytes.
2000 May
Contribution of ryanodine receptor subtype 3 to ca2+ responses in Ca2+-overloaded cultured rat portal vein myocytes.
2001 Apr 6
Smooth muscle-targeted overexpression of insulin-like growth factor I results in enhanced vascular contractility.
2001 Feb
Nitric oxide-mediated arteriolar dilation after endothelial deformation.
2001 Feb
Vascular NAD(P)H oxidase is distinct from the phagocytic enzyme and modulates vascular reactivity control.
2001 Feb
Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system.
2001 Feb
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.
2001 Feb 16
Activity of cardiorespiratory networks revealed by transsynaptic virus expressing GFP.
2001 Jan
Involvement of Ca2+ -activated K+ channels in ginsenosides-induced aortic relaxation in rats.
2001 Jan
Effects of LY117018 and the estrogen analogue, 17alpha-ethinylestradiol, on vascular reactivity, platelet aggregation, and lipid metabolism in the insulin-resistant JCR:LA-cp male rat: role of nitric oxide.
2001 Jan
Effect of dietary vitamin E supplementation on vascular reactivity of thoracic aorta in streptozotocin-diabetic rats.
2001 Jan
Increased dilator response to heptanol and octanol in aorta from DOCA-salt-hypertensive rats.
2001 Jan
In vivo measurement of pulsewave velocity in small vessels using intravascular MR.
2001 Jan
Catecholamine responses to alpha-adrenergic blockade during exercise in women acutely exposed to altitude.
2001 Jan
Effects of acute and chronic hypertension on the labyrinthine barriers in rat.
2001 Jan
Substance P and NPY differentially potentiate ATP and adrenergic stimulated vasopressin and oxytocin release.
2001 Jan
A metabolic fragment of bradykinin, Arg-Pro-Pro-Gly-Phe, protects against the deleterious effects of lipopolysaccharide in rats.
2001 Jan
Inducible and neuronal nitric oxide synthase involvement in lipopolysaccharide-induced sphincteric dysfunction.
2001 Jan
Hepatic neovascularization after partial portal vein ligation: novel mechanism of chronic regulation of blood flow.
2001 Jan
Effect of gamma-melanocyte-stimulating hormones on baroreflex sensitivity and cerebral blood flow autoregulation in rats.
2001 Jan
Increased alpha(1)- and alpha(2)-adrenoceptor-mediated contractile responses of human skeletal muscle resistance arteries in chronic limb ischemia.
2001 Jan
The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo.
2001 Jan 19
Evidence of alpha-adrenoceptor-mediated chronotropic action in children.
2001 Jan-Feb
In vivo regulation of Na/Ca exchanger expression by adrenergic effectors.
2001 Mar
Endothelial cell protein kinase G inhibits release of EDHF through a PKG-sensitive cation channel.
2001 Mar
Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases.
2001 Mar
Topical phenylephrine increases anal canal resting pressure in patients with faecal incontinence.
2001 Mar
Low temperature prevents potentiation of norepinephrine release by phenylephrine.
2001 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Also used as Ophthalmic Solution or oral tablets http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf https://www.drugs.com/dosage/chlorpheniramine-phenylephrine.html
VAZCULEP (phenylephrine hydrochloride) Injection, 10 mg/mL, is injected intravenously either as a bolus or in a dilute solution as a continuous infusion. Dilute before administration. Dosing for treatment of hypotension during anesthesia Bolus intravenous injection: 40 mcg to 100 mcg every 1-2 minutes as needed, not to exceed 200 mcg. Intravenous infusion: 10 mcg/min to 35 mcg/min, titrating to effect, not to exceed 200 mcg/min.
Route of Administration: Intravenous
The hypertrophic phenotype of neonatal rat cardiomyocyte cultures (cardiomyocyte size, sarcomeric organization, total protein synthesis, c-fos expression) mediated by phenylephrine (10 uM) was counteracted by the selective A1 receptor agonist
Substance Class Chemical
Created
by admin
on Fri Dec 15 21:16:06 GMT 2023
Edited
by admin
on Fri Dec 15 21:16:06 GMT 2023
Record UNII
DU5ATO7HYP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHENYLEPHRINE TANNATE
VANDF   WHO-DD  
Common Name English
PHENYLEPHRINE TANNATE [VANDF]
Common Name English
PHENYLEPHRINE TANNATE [WHO-DD]
Common Name English
Code System Code Type Description
FDA UNII
DU5ATO7HYP
Created by admin on Fri Dec 15 21:16:06 GMT 2023 , Edited by admin on Fri Dec 15 21:16:06 GMT 2023
PRIMARY
SMS_ID
100000085298
Created by admin on Fri Dec 15 21:16:06 GMT 2023 , Edited by admin on Fri Dec 15 21:16:06 GMT 2023
PRIMARY
RXCUI
221139
Created by admin on Fri Dec 15 21:16:06 GMT 2023 , Edited by admin on Fri Dec 15 21:16:06 GMT 2023
PRIMARY RxNorm
EVMPD
SUB03778MIG
Created by admin on Fri Dec 15 21:16:06 GMT 2023 , Edited by admin on Fri Dec 15 21:16:06 GMT 2023
PRIMARY
ECHA (EC/EINECS)
215-810-1
Created by admin on Fri Dec 15 21:16:06 GMT 2023 , Edited by admin on Fri Dec 15 21:16:06 GMT 2023
PRIMARY
PUBCHEM
165411843
Created by admin on Fri Dec 15 21:16:06 GMT 2023 , Edited by admin on Fri Dec 15 21:16:06 GMT 2023
PRIMARY
DRUG BANK
DBSALT001555
Created by admin on Fri Dec 15 21:16:06 GMT 2023 , Edited by admin on Fri Dec 15 21:16:06 GMT 2023
PRIMARY
CAS
1416-03-1
Created by admin on Fri Dec 15 21:16:06 GMT 2023 , Edited by admin on Fri Dec 15 21:16:06 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY